ScoMo’s dodgy vaccine doesn’t stop virus spread


As we know, ScoMo’s vaccine choice is a little bit dodgy:


then AZ released some dodgy results a few weeks back:

Today the vaccine dodgening gets wore still, at Bloomie:

A vaccine from the University of Oxford and AstraZeneca Plc shows only a limited ability to stop transmission of the coronavirus despite preventing Covid-19 illness in a majority of those who are infected.

As promising vaccine data keeps rolling in, one of the central unanswered questions has been whether inoculations can not only stop people from getting sick but also slow the spread of the virus, a key element for reopening economies.

Oxford and Astra are the first vaccine developers to unveil data on asymptomatic infection rates in people who received their shot. Overall, it reduced such transmissions by 27% in a large study, according to peer-reviewed results published in the Lancet medical journal on Tuesday.

That’s well below the vaccine’s 70% effectiveness at preventing symptomatic Covid-19 cases overall, though even those results are clouded by questions over its benefits in older recipients.


In short, just forcing travelers to get the shot won’t do squat. You will need to be shot up with ScoMo’s dodgy vaccine as well.

About the author
David Llewellyn-Smith is Chief Strategist at the MB Fund and MB Super. David is the founding publisher and editor of MacroBusiness and was the founding publisher and global economy editor of The Diplomat, the Asia Pacific’s leading geo-politics and economics portal. He is also a former gold trader and economic commentator at The Sydney Morning Herald, The Age, the ABC and Business Spectator. He is the co-author of The Great Crash of 2008 with Ross Garnaut and was the editor of the second Garnaut Climate Change Review.